SCHEMBL425179

SCHEMBL425179

CCc1nnc(NC(=O)c2sc3nc4c(cc3c2N)CN(C(C)C)CC4)s1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 15/20 0.72
KDM4E B2RXH2 5/20 0.72
ALDH1A1 P00352 5/20 0.72
SMN1; SMN2 Q16637 4/20 0.72
POLB P06746 4/20 0.72
LMNA P02545 3/20 0.72
RAB9A P51151 3/20 0.72
RECQL P46063 3/20 0.72
TDP1 Q9NUW8 3/20 0.72
L3MBTL1 Q9Y468 3/20 0.72
NPC1 O15118 2/20 0.72
HTT P42858 1/20 0.72
HPGD P15428 1/20 0.72
RUNX1 Q01196 1/20 0.72
CBFB Q13951 1/20 0.72
KMT2A Q03164 6/20 0.56
MEN1 O00255 4/20 0.56
BLM P54132 1/20 0.56
MCL1 Q07820 1/20 0.56
TP53 P04637 5/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425577 0.90 MAPT (0.74) MAPTKDM4EALDH1A1SMN1; SMN2POLB
SCHEMBL10134467 0.85 MAPT (0.98) MAPTKDM4EALDH1A1SMN1; SMN2POLB
SCHEMBL430884 0.85 MAPT (0.94) MAPTKDM4EALDH1A1SMN1; SMN2POLB
SCHEMBL13186493 0.84 MAPT (0.67) MAPTKDM4EALDH1A1SMN1; SMN2POLB
SCHEMBL13186374 0.80 MAPT (0.76) MAPTALDH1A1SMN1; SMN2POLBTP53
SCHEMBL14955185 0.79 MAPT (0.66) MAPTKDM4EALDH1A1SMN1; SMN2POLB
SCHEMBL429362 0.79 MAPT (0.79) MAPTSMN1; SMN2POLBTP53ADORA2A
SCHEMBL13186359 0.79 MAPT (0.74) MAPTKDM4EALDH1A1SMN1; SMN2POLB
SCHEMBL192652 0.78 MAPT (0.70) MAPTKDM4EALDH1A1SMN1; SMN2POLB
SCHEMBL426238 0.78 MAPT (0.60) MAPTKDM4EALDH1A1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3181568-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS Siga Technologies, Inc. (US) 2017-06-21 EP disclosed
US-20170121344-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2017-05-04 US disclosed
US-20170121344-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2017-05-04 US disclosed
EP-2400845-B1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECH INC (US) 2017-02-22 EP disclosed
US-9301949-B2 Thienopyridine derivatives for the treatment and prevention of dengue virus infections SIGA TECHNOLOGIES, INC. (US) 2016-04-05 US disclosed
US-9301949-B2 Thienopyridine derivatives for the treatment and prevention of dengue virus infections SIGA TECHNOLOGIES, INC. (US) 2016-04-05 US disclosed
WO-2014089378-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2014-06-12 WO disclosed
US-20130129677-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. (US) 2013-05-23 US disclosed
US-20130129677-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. (US) 2013-05-23 US disclosed
US-20120022046-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. 2012-01-26 US disclosed
US-20120022046-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. 2012-01-26 US disclosed
US-20120022046-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. 2012-01-26 US disclosed
WO-2010099166-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022046-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections TTPA, TPMT, SLC19A2 MAPT 138/4885KDM4E 1399/4885ALDH1A1 1271/4885
US-20130129677-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections TTPA, TPMT, SLC19A2 MAPT 85/4885KDM4E 1403/4885ALDH1A1 1400/4885
US-20170121344-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS TTPA, TPMT, SLC19A2 MAPT 85/4885KDM4E 1403/4885ALDH1A1 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.